1Department of Oral Pathology& Microbiolog, King George's Medical University, Lucknow, Uttar Pradesh, India
2Department of Oral Pathology& Microbiolog, King George's Medical University, Lucknow, Uttar Pradesh, India
3Department of Oral Pathology& Microbiolog, King George's Medical University, Lucknow, Uttar Pradesh, India
4Department of General Surgery, Carrier Institute of Medical Sciences and Research Center, Lucknow, Uttar Pradesh, India
Online published on 18 March, 2017.
The first oncolytic virus for cancer treatment was approved in 2005 with combination of chemotherapy, was used for the treatment of upper nasal cancers in China. It was done by the Shanghai Sunway Biotech's, they genetically modified adenovirus H101. Oncolytic viruses target particular effected cell and does not harm human normal tissues. Over the past 15 years, new degrees into the molecular mechanisms of viral cytotoxicity have made available the scientific rationale to design more effective oncolytic viruses. New trials using genetically engineered or genetically modified viral strains of viruses, i.e. adenovirus (ONYX-015 and CV706) and herpes simplex virus 1 along with wild-type Newcastle disease virus (PV701) have been promoting, representing these viruses to be relatively non-toxic and tumor specific. This review article discuss about activity of oncolytic viruses in treatment of head and neck cancer. SEPREHVIR (HSV-1716) completed I phase in OSCC of head and neck cancer. It is also tested for phase III trial in head and neck cancer. Oncolytic viruses will continue repeatedly researched because of their therapeutic outcomes, particularly when used in combination with other treatments such as chemotherapy.
Oncolytic Virus, head and neck cancer, Oral cancer, Oncolytic virotherapy
